- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01586039
Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep
Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep.
The timing and quality of sleep is governed by environmental and physiologic factors. Environmental factors, especially ambient lighting can impact the circadian system and alter the timing and structure of sleep. Light exposure can also acutely alter neural activation state and impair sleep. These effects all demonstrate marked sensitivity to short-wavelength blue light with maximal sensitivity in the 460-480 nm range. The alerting effects of blue light in the evening persist for at least 3-4 hours after the lights are turned off, and can disturb subsequent sleep. Avoiding these deleterious effects of light exposure prior to sleep on subsequent sleep would be beneficial to sleep quality and potentially health.
The investigators will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light. The investigators will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL). In a within-subject design, the investigators will test the hypotheses that exposure to a blue-depleted LED as compared to a CFL exposure at (1) 90 lux or (2) 50 lux will cause significantly:
- Less melatonin suppression between melatonin onset and bedtime;
- Less subjective and objective alerting responses before bedtime;
- Less disruption of nocturnal sleep structure and quality.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Brigham and Women's Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
(i) Aged between 18-30 years to reduce the confounding effects of lens aging on the transmission of light to the retina;
(ii) Non-smoking for at least 6 months;
(iii) Healthy (no medical, psychiatric or sleep disorders);
(iv) No clinically significant deviations from normal in medical history, vital signs, physical examination, blood chemistry and hematology, urine chemistry and ECG;
(v) Women of childbearing potential must agree to use an acceptable method of birth control, and must have a negative urine pregnancy test;
(vi) Body mass index of > 18 or < 30 kg/m2;
(vii) No drugs or medication likely to affect sleep or alertness, as determined by the investigators;
(viii) Habitual caffeine consumption < 300mg per day on average;
(ix) Habitual alcohol consumption < 10 alcoholic units per week on average.
Exclusion Criteria:
(i) History of alcohol or substance abuse;
(ii) Positive result on drugs of abuse screening;
(iii) Current or past history of sleep disorders, including but not limited to obstructive sleep apnea, or any significant sleep complaint;
(iv) Psychiatric disorder;
(v) Recent acute or chronic medical disorder, including but not limited to hepatic impairment and severe chronic obstructive pulmonary disease;
(vi) Visual disorder, including but not limited to color blindness, or family history of glaucoma;
(vii) History of intolerance or hypersensitivity to melatonin or melatonin agonists;
(viii) Pregnancy or lactation;
(ix) Shift work;
(x) Transmeridian travel (2 or more time zones) in past 2 months;
(xi) Any other reason as determined by the Principal Investigator.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Faktoriel opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Compact Fluorescent Light 90 lux
90 lux exposure of a commercially available Compact Fluorescent Light (CFL).
|
We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime.
We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
|
Eksperimentel: Blue-depleted LED light 90 lux
90 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime.
We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
|
Aktiv komparator: Compact Fluorescent Light 50 lux
50 lux exposure of a commercially available Compact Fluorescent Light (CFL).
|
We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime.
We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
|
Eksperimentel: Blue-depleted LED light 50 lux
50 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime.
We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Melatonin Suppression
Tidsramme: 6-h constant posture interval of the light exposure
|
Melatonin suppression is measured as the percentage of melatonin AUC relative to the AUC measured in dim light on the previous day.
AUC was calculated during the 6 h of light exposure and the corresponding 6-h interval 24 hours earlier.
Higher values indicate more light-induced melatonin suppression.
|
6-h constant posture interval of the light exposure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sleep Structure
Tidsramme: 8-h time in bed immediately following CFL/LED light exposure.
|
Sleep efficiency assessed by polysomnography.
Sleep efficiency refers to the percentage of time a person sleeps, in relation to the amount of time a person spends in bed trying to sleep.
The percentage is calculated by dividing the Total Sleep Time by the Total Time in Bed.
|
8-h time in bed immediately following CFL/LED light exposure.
|
|
Sleep Quality
Tidsramme: First morning after 8-h time in bed immediately following CFL/LED light exposure.
|
Self-reported sleep quality was assessed using a post sleep questionnaire.
Score on subjective scale range 1-7, higher scores indicate higher sleep quality.
|
First morning after 8-h time in bed immediately following CFL/LED light exposure.
|
|
Subjective Alerting Response
Tidsramme: 6-h constant posture interval of the light exposure.
|
Self-reported sleepiness measured during the light exposure using the Karolinska Sleepiness Scale (KSS).
Range of scores 1-9, higher score indicate higher subjective sleepiness.
Measures were taken hourly throughout the 6-hour constant posture interval of the light exposure and then averaged to calculate a single value per participant.
|
6-h constant posture interval of the light exposure.
|
|
Objective Alerting Response
Tidsramme: 6-h constant posture interval of the light exposure
|
Mean reaction time assessed using the 10-minute psychomotor vigilance test.
Higher numbers indicate slower reaction times indicating less alertness.
Measures were taken hourly throughout the 6-hour constant posture interval of the light exposure and then averaged to calculate a single value per participant.
|
6-h constant posture interval of the light exposure
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Steven W Lockley, Ph.D., Brigham and Women's Hospital; Harvard Medical School
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- 2011-P-002834
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Non-visual Photoreception
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityAfsluttetVisual Health of Virtual RealityKina
-
University of Illinois at Urbana-ChampaignAfsluttetKognitiv forandring | Behandling, Visual SpatialForenede Stater
-
University of Illinois at Urbana-ChampaignAfsluttetKognitiv forandring | Arbejdshukommelse | Hæmning (psykologi) | Behandling, Visual SpatialForenede Stater
-
New York City Health and Hospitals CorporationAfsluttetGrøn stær | Nethindesygdom | Visual Pathway DisorderForenede Stater
-
Neuro-Eye Diagnostic Systems, LLCNeuro-ophthalmology of Texas PLLCTilmelding efter invitationMakula sygdom | Visual Pathway Disorder | SynsnervesygdomForenede Stater
-
University of ZurichBalgrist University HospitalRekruttering
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeGliom af lav grad | Tilbagevendende Visual Pathway Gliom | Refractory Visual Pathway Gliom | Tilbagevendende pilocytisk astrocytom i barndommen | Tilbagevendende neurofibromatose type 1 | Refraktær neurofibromatose type 1Forenede Stater
-
Cairo UniversityRekrutteringVisual til at sammenligne det visuelle resultat mellem AcrySof™ IQ Vivity™ og TECNIS Synergy™ intraokulær linse (model ZFR00V)Egypten
-
Fondazione G.B. Bietti, IRCCSAfsluttetGrøn stær | Optisk neuropati, iskæmisk | Optisk nerve | Visual Pathway Disorder | Neural ledningItalien
Kliniske forsøg med Visible light
-
RxSight, Inc.Tilmelding efter invitationAphakia KataraktForenede Stater
-
Icahn School of Medicine at Mount SinaiRekruttering
-
Dent Neuroscience Research CenterGenentech, Inc., a subsidiary of F. Hoffman-La Roche AG; Monogram Biosciences...Aktiv, ikke rekrutterendeMultipel sclerose | Recidiverende remitterende multipel skleroseForenede Stater
-
Stanford UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Rekruttering
-
RxSight, Inc.Afsluttet
-
United States Air Force Research LaboratoryOhio State University; Uniformed Services University of the Health Sciences og andre samarbejdspartnereAktiv, ikke rekrutterendeFysiologisk velværeForenede Stater
-
LumiThera, Inc.RekrutteringTør aldersrelateret makuladegenerationNorge
-
University of ArizonaNational Cancer Institute (NCI)AfsluttetSolskadet hudForenede Stater
-
LumiThera, Inc.National Eye Institute (NEI)Aktiv, ikke rekrutterendeTør aldersrelateret makuladegenerationForenede Stater
-
Lara McKenzieAfsluttet